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1. INTRODUCTION 
The mammalian liver has a remarkable ability to restore its original size after sub-
stantial tissue loss by inducing massive cell proliferation. Despite the enhanced 
regenerative capacity, liver diseases have high mortality rate, and the numbers are 
increasing every year. Cirrhosis and primary liver cancer – the end-stages of 
chronic liver diseases – have only one treatment option – liver transplantation. 
Since the demand for donor organs surpasses their availability, development of 
alternative treatment methods has become increasingly important. In order to 
generate new therapeutics it is necessary to understand the cellular and molecular 
mechanisms that control liver regeneration and disease progression. 
A common feature in many chronic liver diseases is the appearance of proli-
ferative ductular structures (ductular reactions, DRs), and deposition of extra-
cellular matrix (ECM). As the disease progresses, DRs and ECM gradually 
replace parenchyma, causing decline in liver functioning. In order to find ways 
to prevent or reverse these processes, it is important to identify the origin of 
DRs, understand their pathogenesis, and determine the impact of ECM compo-
nents on cell behavior. 
Tissue specific somatic stem cells are believed to be slowly cycling cells 
residing in unique niches. In many tissues these cells are crucial for tissue main-
tenance in normal conditions and for the recovery after injury, as they give rise 
to rapidly dividing transit amplifying cells, which replenish the lost cells. The 
identity of liver stem cells and their contribution in liver maintenance and 
regeneration is still under debate. Hence, the main objective of this thesis was to 
identify slowly cycling progenitor cells in an adult liver, and study their beha-
vior in liver injury by using different liver injury mouse models. Next we exa-
mined which ECM changes are induced in response to different liver injuries 
and how these changes could affect liver regeneration. We also described the 
microenvironment that promotes cell proliferation and enhances fibrosis in 
Dupuytrenʼs disease (DC). Although DC is not liver-related disease, fibrosis in 
all organs has similar histological features, and has similarities in cell signaling. 
Finally, we set out to identify small molecule compound that would inhibit 
AKT signaling pathway, which is commonly hyperactivated in liver cancers and 
other malignancies of various origin.  
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2. LITERATURE OVERVIEW 
2.1. General overview of liver functions 
The liver is the largest visceral organ of the body exhibiting both exocrine and 
endocrine properties [1]. It has more than 500 different functions that play 
major roles in the control of normal physiological processes of the entire 
organism. Some of the most important functions include bile secretion, glyco-
gen storage, regulation of cholesterol levels and urea metabolism, drug detoxi-
fication, and secretion of various proteins. Constant exposure to environmental 
agents and toxins often results in liver diseases caused by severe changes in 
liver physiology and decreased functioning; and since the liver is involved in 
the regulation of a large number of pathways, it is no surprise that liver diseases 
are among the leading causes of deaths today [1].  
 
 
2.2. Liver cell types and basic anatomy 
Liver contains many different cell types, each one of them having their own 
particular role in their own particular niche. Proper hepatic functioning requires 
coordinated work of all of these cells. Two major cell types in the liver are 
hepatocytes and cholangiocytes (also known as bile/biliary duct cells), consti-
tuting  ̴ 70% and  ̴ 3% of the cell population, respectively. Other cell types 
include Kupffer cells (resident liver macrophages), hepatic stellate cells (also 
known as Ito cells), endothelial cells, sinusoidal endothelial cells and pit cells 
(liver-specific natural killers). While hepatocytes and bile duct cells are derived 
from endoderm, the rest of the cells are of mesodermal descent [1, 2].  
The smallest functional unit of the liver, the lobule [3], consists of hepato-
cytes which are organized in plates and are lined by sinusoids that radiate 
toward the central vein situated in the middle of the hexagonal lobule (Figure 
1A,B). The lobule can be divided into zones, based upon decreasing oxygen 
concentration: periportal (zone 1), transitional (zone 2), and pericentral (zone 3) 
(Figure1B) [4]. Each tip of the lobule contains a triad of vessels – a portal vein, 
bile duct and hepatic artery – the “portal triad”. Blood enters the lobule via 
portal vein and hepatic artery, flows in sinusoidal capillaries, where venous and 
arterial blood mix together, and leaves through the central vein. Hepatocytes 
have direct contact with blood plasma in the sinusoidal space where they absorb 
toxins and metabolites [5]. Concomitantly, bile acids and salts secreted by 
hepatocytes move in the bile canaliculi toward bile ducts in an opposite 
direction to the bloodflow. Bile ducts are formed by the second largest cell 
population in the liver, the biliary epithelial cells. These cells control bile flow 
rate and its pH, and secrete water and bicarbonate [1]. 
 
 
12 
 
 
Figure 1. Architecture of the liver.  
(A) Liver cell types and their organization in the liver. Blood enters the liver via portal 
vein (PV) and hepatic artery (HA), and flows in sinusoids toward the central vein (CV). 
Hepatocytes secrete bile that flows in bile canaliculi toward bile ducts (BD).  
(B) Structure of the liver lobule. Hepatocyte cords radiate from CV (in the middle of the 
hexagonal lobule) toward portal triads. The direction of blood and bile flow, and lobule 
zones are also shown [4].  
 
 
2.3. Embryonic development of hepatocytes and 
cholangiocytes 
Hepatocytes and cholagiocytes originate from a common precursor, the hepato-
blasts, which are derived from the definitive gut endoderm. At E9.5 of mouse 
development, the laminin-rich basal layer surrounding the hepatic endoderm 
disintegrates, and hepatoblasts migrate into septum transversum where they 
form the liver bud [1, 6–8]. Initially, bipotential hepatoblasts express fetal liver 
marker α-fetoprotein (AFP) as well as markers associated with both hepatocytes 
(hepatocyte nuclear factor alpha, HNF4α and albumin, ALB) and cholangio-
cytes (cytokeratin 19, CK19). As hepatoblasts begin to differentiate at  ̴ E13.5 in 
mouse and 56–58 days after conception in human, the hepatic precursors adja-
cent to the portal veins increase their CK19 expression, decrease their HNF4α 
and ALB expression, and eventually differentiate into cholangiocytes. Con-
currently, the hepatoblasts which are not in contact with portal veins and reside 
in the parenchyma, gradually differentiate into hepatocytes [9–11]. Although 
these differentiation processes start at the embryonic stage, the cells become 
fully mature only postnatally.  
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2.4. Signaling pathways in liver development 
All processes in liver development, including bud formation, cell specification, 
differentiation, and maturation, involve coordinated signaling between cells as 
well as their environment. The onset of liver formation is dependent on the key 
signaling pathways controlled by fibroblast growth factor (FGF) and bone 
morphogenetic protein (BMP) [12, 13]. It has been shown that if the signaling 
of either of them is blocked, liver formation is not induced [12, 14]. Homeo-
domain factor Hex and zinc finger transcription factors Gata4 and Gata6 are 
essential for liver bud formation and hepatoblast delamination [15–18]. 
Although Hex-/-  mouse mutants are able to form initial liver bud, further bud 
development in these embryos is arrested and hepatoblasts are not able to in-
vade the surrounding stromal tissue [17]. Similarly to Hex mutants, the liver 
development in Gata6-/- mouse embryos stops shortly after initial bud formation 
[18]. Hepatoblast delamination involves also rearrangement of the extracellular 
matrix (ECM), since the liver bud is surrounded by matrix consisting of lami-
nin, nidogen, type IV collagen, fibronectin (FN), and heparan sulfate proteogly-
cans [19]. One of the transcription factors responsible for ECM remodeling is 
homeobox transcription factor Prox1 [20]. Prox1 downregulates E-cadherin in 
invading hepatoblasts and controls the expression of several ECM proteins and 
remodeling enzymes such as matrix metalloproteinase-2 (MMP-2) that are 
necessary for the disruption of the basement membrane and subsequent delami-
nation [20–22]. 
Transcription factors, signaling pathways and corresponding signal transdu-
cers essential for hepatocyte differentiation and maturation include Wnt, Onco-
statin M (OSM), glucocorticoids, hepatocyte growth factor (HGF), FoxA1/2, 
hepatocyte nuclear factor 1 alpha and beta (HNF1α and β), HNF4α, CCAAT-
enhancer-binding protein (C/EBP) and HNF6 (reviewed in [5, 23]). Cholangio-
cyte  differentiation and maturation is controlled by Notch, transforming growth 
factor beta (TGFβ), FGF and Wnt signaling that promote the expression of 
transcription factors needed for biliary fate (HNFβ1, Sox9 (Sex Determining 
Region Y-Box 9), and Oncostatin 1 and 2) and simultaneously suppress hepato-
genic factors (HNF4 and C/EBP) (reviewed in [5, 23]). Pathways mentioned in 
this section represent only a subset of those that are known to play major roles 
in liver development. The entire network of factors is much more complicated 
and our understanding of this network is far from complete. 
 
 
2.5. Liver in homeostasis and injury 
Tissue homeostasis is achieved predominantly by two mechanisms: cell dupli-
cation and differentiation from stem/progenitor cells. For example, stem/pro-
genitor cells provide a continuous supply of all cell lineages in the skin and 
intestine [24, 25].  Although these tissues have high cellular turnover rate, their 
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stem cell pool is able to maintain the cellular homeostasis and replenish lost 
cells after tissue damage throughout the entire life.  
The liver on the other hand is a quiescent organ – only a small number of 
cells, 1 in 20,000 to 40,000 hepatocytes, are actively cycling in adult liver at 
any given time point [26]. Despite their slow cycling speed, the differentiated 
cells in the liver are believed to be capable of maintaining cellular homeostasis 
without any contribution from stem/progenitor cells. More than 30 years ago a 
“streaming liver” hypothesis was proposed, stating that new hepatocytes that are 
produced at the portal tract, move toward central vein, acquire new functions 
along the way, and populate the entire lobe over time [27]. This hypothesis 
gained support in 2011 by Furuyama et al., who showed in lineage tracing 
experiments that hepatocytes originate from Sox9+ bile duct cells and “stream” 
in a portal-to-centrilobular direction [28]. However, tamoxifen injection that 
was used to activate recombination in Sox9+ biliary cells, induces ectopic 
expression of Sox9 also in hepatocytes, therefore, one cannot exclude the possi-
bility that new liver cells were actually derived from tamoxifen-induced Sox9+ 
hepatocytes [29]. As most studies contradicted the “streaming” hypothesis [30–
32], it was generally accepted that liver homeostasis is maintained by simple 
replication of existing differentiated cells. Recently, a new mechanism of 
hepatocyte maintenance was demonstrated [33]. According to this concept, 
there is a population of cells – the hepatocyte stem cells – consisting of mainly 
diploid Axin2+ pericentral hepatocytes that can self-renew, have elevated 
proliferation rate, differentiate into more mature polyploid hepatocytes, and 
replace 40% of hepatocytes in centrilobular-to-portal direction in one year. This 
is similar to the “streaming liver” hypothesis: both concepts state that only a 
small subset of cells supplies new hepatocytes in liver homeostasis, and cell 
replacement involves unidirectional “streaming”. However, cell migration in 
this new model is in opposite direction – from central vein to portal triad. Until 
these results are confirmed by others using independent methods, liver physio-
logical maintenance is still considered to be supported equally by all hepato-
cytes.   
Liver has also a remarkable regenerative potential along with a unique 
feature: the recovery mechanism is thought to be determined by the type of 
injury. After partial hepatectomy (PH), the liver mass is reinstated within 2–3 
weeks by replication and hypertrophy of existing liver cells in rodents [34, 35]. 
In response to chronic liver injury when hepatocyte and/or cholangiocyte pro-
liferation is abrogated, cells with oval-shaped nuclei, referred to as “oval cells” 
in rodents, and ductular reactions (DRs) in humans, accumulate typically 
around the portal areas in the liver [36–38]. These rapidly proliferating cells are 
considered to be facultative liver progenitor cells contributing to liver repair, 
since they can differentiate into both, hepatocytes and cholangiocytes [39–42]. 
Emergence of ductular reactions has been documented in a variety of human 
liver diseases [43], however, their origin, true nature, and role in liver regene-
ration and homeostasis are still unresolved. 
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2.6. Hepatic precursors in normal liver 
Stem cells possess two unique characteristics that distinguish them from all 
other cell types: they are capable of self-renewal through numerous cell divi-
sions and they can differentiate into a cell with more specialized functions [44]. 
Embryonic stem cells, which originate from the inner cell mass of the blasto-
cyst, are pluripotent as they can generate any cell type in the body [45, 46]. 
Multipotent stem cells, such as adult stem/progenitor cells (also called somatic 
stem cells), which reside in specific niches in most adult tissues and participate 
in the maintenance of homeostasis in physiological and/or pathological con-
ditions, sometimes after being inactive for long periods of time [47], can give 
rise to only a limited number of differentiated cell progenies.  
Identifying and localizing somatic stem cells in the liver has proven to be a 
challenge as the liver is a relatively quiescent organ and does not need pro-
genitor activity in normal conditions. Also, the lack of specific liver stem cell 
markers has hindered their characterization. One of the main focus points in 
liver stem cell research has been uncovering the origin of ductular reactions – 
the transit-amplifying cells – presumably derived from hepatic stem cells [48]. 
Ductular reactions occur in virtually all acute and chronic liver diseases of 
biliary and nonbiliary origin [48], and their contribution to liver regeneration 
has been consistently demonstrated in several species. Over time, various pos-
sible origins for ductular reactions have been proposed, including: 1) biliary 
duct system and canals of Hering, 2) mature hepatocytes, 3) bone marrow cells, 
and 5) mesenchymal stromal cells and hepatic stellate cells [26, 49].  
 
 
2.6.1. Hepatic precursors in biliary duct system 
Considering the appearance of ductular reactions in portal areas in severely 
injured livers, it is not surprising that biliary ducts and the canals of Hering 
(terminal branches of the biliary duct) have been thought to be the niche of 
hepatic precursors. Furthermore, many markers such as CK19, CK7, epithelial 
cell adhesion molecule (EpCAM), osteopontin (OPN), A6, and CD133, which 
are widely used to detect or isolate progenitor cells from injured liver, are also 
expressed by biliary cells in normal liver [49]. The canals of Hering are lined 
partly by hepatocytes and partly by cholangiocytes, and can be viewed as a 
bridge between the hepatocyte canalicular system and the biliary tree [38]. The 
presence of hepatic precursor cells in the canals of Hering has been described in 
postnatal and adult human livers [50, 51]. These cells were positive for 
EpCAM, CK19, and CD133 and also expressed low levels of albumin, albeit at 
a significantly lower level than mature hepatocytes. They differentiated into 
cholangiocytes and hepatocytes in vitro and EpCAM+ cells derived from 
postnatal liver where able to repopulate the liver of immunodeficient mice [50]. 
Tanimizu et al. showed  also that EpCAM+ cholangiocytes isolated from neo-
natal mice converted into hepatocytes in vitro [52]. However, this capability 
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decreased gradually and was lost completely in adult mice. By comparing 
neonatal and adult cholangiocytes, they discovered that the levels of transcrip-
tion factors important in hepatocyte differentiation such as HNF4α and C/EBPα 
were upregulated in neonatal cholangiocytes. Adult biliary cells, on the other 
hand, showed elevated expression of factors related to cholangiocyte differen-
tiation. These results indicate that cholangiocytes lose their bidirectional diffe-
rentiation potential during epithelial maturation. In contrast, Kamiya et al. 
demonstrated that adult stem cell population exists within cholangiocyte 
compartment even in 3-month-old mice [53]. After identifying CD13, CD133, 
EpCAM, and CD49f as markers expressed in liver precursors, they found that 
these cells can form colonies containing both, ALB+ hepatocytes and CK19+ 
bile duct cells, indicating that at least a subset of cholangiocytes may preserve 
their proliferative capability and bipotency. A comparative study with CD133+ 
cells that were isolated from normal adult liver (CD133+ cholangiocytes) and 
chronically injured liver (CD133+ cholangiocytes and ductular reactions) 
showed that although CD133+ cells from normal liver could form  small 
colonies in vitro, they only expressed biliary marker CK7 [54]. CD133+ cells 
isolated from injured liver formed small and large colonies, where small 
colonies expressed only CK7, whereas cells in large colonies gradually diffe-
rentiated and became either ALB+, CK7+, or ALB+CK7+. This shows that 
cholangiocytes are lineage-committed in normal liver, certain injuries, however, 
may induce some of them to proliferate and give rise to bipotential progenitors. 
Fate-tracing studies based on cholangiocyte-specific gene expression (OPN and 
hepatocyte nuclear factor 1 beta, HNF1β) also suggest that there are cells within 
biliary compartment which generate ductular reactions and these can diffe-
rentiate into hepatocytes after certain liver injury [41, 55]. Other fate-tracing 
studies where CK19-Cre and HNF1β-Cre mice were used argue against this 
phenomenon, showing that although cholangiocytes give rise to DRs, new 
hepatocytes arise from pre-exicting hepatocytes by self-duplication and contri-
bution from biliary-derived progenitor cell population is negligible in different 
injury models [56–58].  
These examples suggest that although there are contradictory results when it 
comes to the differentiation potential of adult biliary cells and their progeny, 
evidence strongly suggest possible lineage-connection between cholangiocytes 
and facultative liver progenitor cells.    
 
 
2.6.2. Hepatocytes as hepatic precursors 
Cells within ductular reactions are variable in size and immunophenotype, 
ranging from 6 µm in diameter (size of the smallest cholangiocytes) to 40 μm 
(average size of hepatocytes); and express hepatic antigens such as HepPar1, 
ALB, and alpha-1-antitrypsin (AAT), in addition to biliary antigens [38]. 
Morphology of DRs depends largely on the type of liver disease or injury 
model. In addition, although ductular reactions predominantly appear peri-
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portally, they can also be found around central vein, in a distance from the bile 
ducts [59]. These observations imply to the possibility of hepatocytes being the 
source for DRs, at least in certain injury conditions.  
Indeed, in vitro studies have shown that hepatocytes can transdifferentiate 
into ductular cholangiocytes in three-dimensional organoid culture system [60] 
and hepatocyte-to-cholangiocyte/DR conversions have been demonstrated in 
chronically injured livers of transgenic mice [61–65]. However, the extent of 
transdifferentiation appears to be dependent on the mouse model, injury type, 
and method of identification. For example, in a lineage-tracing experiment with 
Alb-CreERT2; R26RlacZ+ mice, over 60% of new ductular cells were derived 
from hepatocytes in response to chronic liver injury induced by DDC-treatment 
(3,5-diethoxycarbonyl-1,4-dihydrocollidine, DDC) [64], whereas only 2% of 
DRs were derived from hepatocytes using hepatocyte-specific MX dynamin-
like GTPase 1 (Mx1)-Cre;R26RlacZ+  mouse model [63]. On the other hand, no 
hepatocyte-derived biliary cells were found in fate-tracing experiment with 
R26-EYFP mice, when hepatocyte-specific EYFP expression was induced with 
adeno-associated virus (AAV)8-Ttr-Cre construct [30]. Experiments with 
hepatocyte-chimeric fumarylacetoacetate hydrolase (FAH) mouse model have 
shown small contribution from hepatocytes [65].   
In addition to the differences in the model systems, contrasting results can 
often be caused by different sets of antigens that investigators use to identify 
ductular reactions. OPN, Sox9, A6 and CK19 are some of the most well-known 
and used DR markers, however, their expression can vary greatly in different 
conditions. As demonstrated by Yanger et al., 48% of OPN+ cells but only 14% 
of CK19+ cells were derived from hepatocytes after DDC-treatment [61]. This 
discrepancy was even greater after bile duct ligation, when OPN+ cell number 
was 30 times higher than CK19+ cell number, while Sox9 and A6 expression 
levels fluctuated between these extremes. This shows that different types of 
injuries can induce different types of DRs with various immunophenotypes, and 
suggests that hepatocyte-to-cholangiocyte conversion is a stepwise process with 
OPN being the earliest and broadest indicator for conversion, and CK19 the 
marker for the differentiation end point. It is not yet known whether all hepato-
cytes are capable of transdifferentiation or if it is a characteristic of particular 
hepatocytes.  
 
 
2.6.3. Bone marrow-derived hematopoietic  
stem cells as hepatic precursors 
Bone marrow derived hematopoietic stem cells can give rise to many different 
cell types, however, data gathered so far suggest that they are not the source of 
hepatic progenitor cells. Experiments with FAH-deficient mice have shown that 
although transplanted bone marrow cells were able to restore liver function and 
FAH expression in hepatocytes, it was not through transdifferentiation into liver 
cells rather via fusion with host hepatocytes [66–68]. Furthermore, when bone 
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marrow from transgenic green fluorescent protein (GFP) mice was transplanted 
into immunodeficient and/or immune-competent mice, no evidence of bone 
marrow-derived liver specific cells were found in normal liver or after toxic 
liver injury [69]. These results correlate with data from rat experiments where it 
was demonstrated that hepatic progenitor cells and hepatocytes are not derived 
from bone marrow cells [70]. 
 
 
2.6.4. Mesenchymal stromal cells and  
hepatic stellate cells as hepatic precursors 
Mesenchymal stromal cells (MSCs) are multipotent cells residing in the bone 
marrow, but can also be found in the connective tissues of most organs, 
including the liver. Although MSCs originate from the mesoderm, they have the 
ability to differentiate into cells of other lineages [71]. MSCs isolated from 
adipose tissue, bone marrow and umbilical cord-blood can differentiate into 
hepatocytes in vitro and in vivo [72–74] and since MSCs are relatively abundant 
and easily accessible, they show a great potential in treating liver diseases. It is 
not known whether transdifferentiation of extrahepatic MSCs into liver cells 
occurs also naturally in the body. Studies with liver-resident MSCs – hepatic 
stellate cells – have resulted in conflicting conclusions: there are reports sup-
porting [75, 76] and refuting [77, 78] a role for hepatic stellate cell population 
as facultative stem cells. Since MSCs are plastic in their differentiation poten-
tial, one cannot rule out the possibility of mesenchymal stellate cells being the 
stem cell pool for epithelial liver cells. It has been suggested that there may be 
even a common organ-specific meso-endodermal precursor cell in an adult liver 
[79]. In a work by Conigliaro et al. it was demonstrated that liver precursors 
with novel immunophenotype (Sca1+CD34-CD45-ALB-) can give rise to either 
mesenchymal or epithelial subpopulations in vitro; and to hepatocytes and 
stellate cells in vivo [79]. It has to be noted, however, that these precursors were 
derived from fetal or neonatal mice. Hence, their existence and input in homeo-
stasis and regeneration in mature liver remain to be discovered. 
 
 
2.6.5. Quiescent stem cells in various compartments 
Somatic stem cells are considered to have slow division rate in normal condi-
tions, a feature that has been exploited in the label-retaining cell (LRC) assay to 
identify tissue specific stem cells [80–83]. In LRC assay, cells are first pulse-
labeled with nucleoside analogues (such as 5-bromo-2-deoxyuridine, BrdU or 
5-Ethynyl-2-deoxyuridine EdU) and the retention of nuclear label after a chase 
period indicates no or minimal proliferation. As the liver itself is quite quiescent 
organ, identifying quiescent adult liver stem cells has not been an easy task. For 
this reason LRC assay in combination with moderate hepatic injury, which 
should induce quiescent stem cells to proliferate, was used to locate BrdU-
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retaining cells [84]. With this strategy four possible stem cell niches were 
identified: the canal of Hering, intralobular bile ducts, periductal “null” mono-
nuclear cells (negative for OV-6, ALB, CD45 and desmin), and peribiliary 
hepatocytes [84]. Peribiliary hepatocytes were later hypothesized to be derived 
from the cells in the canals of Hering but the origin of “null” cells remained un-
clear. In another report, where LRC assay was performed in normal liver with a 
chase period of 23 months, the label-retaining BrdU+ cells were shown to locate 
periportally and very rarely pericentrally [85]. Again, “null” cells appeared after 
injury, however, in this report no BrdU-containig bile duct cells were identified. 
Since active DNA synthesis is the prerequisite for BrdU incorporation, it is 
possible that different injury methods used in these studies activated the prolife-
ration in different cell compartments, which could explain somewhat different 
results. Although both these reports indicated that liver contained quiescent 
cells, their contribution to liver regeneration remained unresolved. 
The inconclusive data regarding the origin, location, and contribution of 
hepatic progenitor cells point to the possible existence of multiple origins for 
these cells. One can speculate that the ability to supply new cells from diverse 
sources is the reason behind the amazing regenerative capacity of the liver. 
Future research will have to determine the exact mechanisms involved in liver 
maintenance.  
 
2.7. Stem cell niche 
In most postnatal tissues, stem cells are located in specialized microenviron-
ments, i.e., niches, where they are maintained in optimal conditions and often in 
a relatively quiescent state. Neural and metabolic signaling, as well as inter-
actions with other cellular and extracellular components within and outside the 
niche are crucial for their preservation and activation [86, 87]. Experiments in 
C.elegans and D.melanogaster have shown that germline stem cells need 
certain proximity to or direct contact with particular neighboring somatic cells 
to maintain their proliferative properties [88–90]. The importance of a specia-
lized microenvironment is exemplified by the fact that upon depletion of endo-
genous germline stem cells, the empty niche can be populated by adjacent 
somatic cells, which are then stimulated to proliferate by the niche environment 
[91]. 
Organs with high cellular turnover rate such as hematopoietic system, skin, 
testis, and the gastrointestinal tract appear to have the most clearly defined stem 
cell niches [92]. But also other organs, which do not have as high degree of 
steady-state cell turnover, such as the brain, seem to have designated stem cell 
niches [92]. Defining the liver stem cell niche has proven to be a challenge, as 
the nature of resident liver stem cells has remained elusive, however, the niche 
and the signaling pathways that promote diverse processes in ductular reactions 
have been studied extensively.  
The ductular reaction comprises several different processes, all contributing 
to the niche formation. These include accumulation of reactive progenitors, 
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infiltration of inflammatory cells, activation and accumulation of liver non-
parenchymal cells in the vicinity of DRs, deposition and rearrangement of 
ECM, and activation of various signaling pathways [48].  
 
 
2.7.1. Signaling in DRs 
Lymphocytes and macrophages appear around DRs of injured and diseased 
livers in mice, rats and humans [93–96]. Inflammatory cells influence the 
behavior of progenitors in DRs by regulating the expression of different 
transcription factors and cytokines, and modulating the composition of matrix. 
Macrophages have been shown to control the proliferation, differentiation, and 
invasion of progenitor cells [95–98]. They produce cytokines like tumor 
necrosis factor alpha (TNFα), interleukin-6 (IL-6), TGFβ, and TNF-like weak 
inducer of apoptosis (TWEAK) that are important for the inititation and expan-
sion of ductular reactions [98, 99]. Hepatic stellate cells and portal myofibro-
blasts, the main sources of liver extracellular matrix [100], are activated in 
injured livers and, in response, increase ECM deposition around DRs [101]. In 
addition, they produce a variety of bioactive molecules that promote progenitor 
proliferation or specify their differentiation pathway [102]. Increasing evidence 
suggest that macrophages, stellate cells, and myofibroblasts work together in 
creating a suitable microenvironment for liver regeneration [96]. Coordinated 
Wnt signaling from macrophages and Notch signaling from myofibroblasts are 
shown to be essential for determing the fate of DR cells [96, 103]. This disco-
very is not unexpected since activated Wnt and Notch signaling are common 
among different stem cell systems; and ectopic activation of Notch signaling 
has been shown to reprogram immature hepatocytes into biliary cells [104]. 
Boulter et al. demonstrated that Notch signaling drives the differentiation from 
bipotential progenitors into cholangiocytes after DDC-induced biliary liver 
damage [96]. In this type of injury the DRs are surrounded by layers of myo-
fibroblasts that express Notch ligand Jagged-1, and by thick sheath of collagen I 
that prevents their contact with macrophages outside the niche. Following CDE-
diet-induced hepatocellular injury, the accumulation of myofibroblasts is not as 
extreme and collagen I deposition is markedly decreased, allowing cell-cell 
contact between progenitors and macrophages. As a result, Wnt signaling from 
macrophages reaches progenitor cells, Wnt target Numb is upregulated and 
Notch becomes downregulated, forcing cells to suppress biliary differentiation 
and aquire hepatocyte specification [96]. Interestingly, Wnt activation in macro-
phages occured after phagocytizing hepatocyte debris, suggesting that macro-
phages adjust their Wnt signaling according to the condition hepatocytes are in. 
Wnt signaling has been shown to direct stem cell differentiation also in the 
epidermis [105] and skeletal muscle [106]. In hematopoietic system, however, 
the Wnt pathway supports stem cell proliferation [107] and in the intestinal 
epithelium it has dual role – proliferative and differentiative [108, 109]. Many 
other pathways implicated in DRs, including Hedgehog (Hh), nuclear factor-κB 
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(NF-κB), TGF-β/BMP, phosphatidylinositol 3-kinase(PI3K)/AKT, and Janus 
kinase/ signal transducers and activators of transcription (JAK/STAT) pathway, 
have been identified in other stem cell systems, as well, but the outcome of their 
activation can vary between tissues [48, 110], demonstarting that stem cell 
niches in different tissues are similar but not identical. 
 
 
2.7.2. General overview of ECM  
ECM is a complex and dynamic network, actively participating in organ 
development, maintenance and repair by modulating the production, arrange-
ment and degradation of individual components. ECM not only provides the 
space, physical support and protection for the cells but also influences their 
behavior through cell-ECM connections and by regulating its physical pro-
perties such as stiffness, porosity, thickness and orientation [111, 112]. Power-
ful demonstration of the importance of ECM comes from the experiments with 
decellularized organs, in which only the ECM is left intact. When these ECM-
scaffolds are inoculated with new cells, they are able to re-populate the organ 
and re-establishe its function [113]. 
The main structural ECM components include collagens, elastins, fibro-
nectins (FNs) and laminins. Collagen, the most abundant protein in the ECM, 
gives strength to the tissue while elastins provide flexibility. Laminins, which 
are found in the basement membrane, and FN are both responsible for cell 
attachment to the matrix via integrins [114]. Proteoglycans contribute to the 
ECM assembly by filling the extracellular interstitial space in hydrogel form 
[112]. In addition to their structural properties, these proteins participate in cell 
migration, differentiation, inflammation, wound healing, and regulate numerous 
signaling cascades [114]. ECM maintenance and remodeling is controlled by 
matrix metalloproteinanses (MMPs) and tissue inhibitors of MMPs (TIMPs) 
[115]. Tight regulation of MMP and TIMP activities is essential for correct 
ECM homeostasis in tissues and their imbalance can lead to failures in organ 
functioning. The importance of ECM in normal physiology is illustrated by the 
fact that abnormal changes in ECM structure and quantity are prominent in 
many genetic and a wide variety of aquired human diseases [116]. These in-
clude cardiovascular, pulmonary, renal, intestinal, neurodegenerative, and con-
nective tissue disorders [116]. Furthermore, tumor development is associated 
with altered ECM composition. 
 
 
2.7.3. ECM in ductular reactions 
Accumulative deposition of ECM (mostly collagen I) is also a hallmark of a 
progressive chronic liver disease [114]. The severity of the disease is in corre-
lation with not only the increasing number of collagen producing myofibro-
blasts [117] but with the magnitude of progenitor cell activation and DR 
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response, as well [94, 118]. It is not yet clear whether the changes in the ECM 
are necessary for progenitor activation or are the expanding liver progenitors 
driving matrix remodelling and deposition. Experiments with the CDE dietary 
model suggest that myofibroblast activation and ECM deposition (collagens I 
and III) precede ductular reactions to provide a supportive niche for progenitor 
cell proliferation, migration, and differentiation [101]. However, it has been 
shown that in certain fibrotic conditions, hepatic progenitor cells could also 
induce collagen accumulation [119]. Leaving aside the order of these events, the 
fact that liver progenior cells are found outside the protective ECM cocoon very 
rarely [101] indicates that the ECM is a key player in DR niche system.  
The ECM has an important part in all known stem cell niches, although its 
complexity varies considerably between different organs (reviewed in [111]). 
Since stem cells in different tissues have unique properties, the composition of 
ECM has to be adapted accordingly in order to protect and support their indi-
vidual capabilities. During aging the niche-specific ECM composition changes, 
which may be one of the reasons why aged niches possess decreased ability in 
maintaining stem cell properties [113].  
As described in the previous chapter, in the liver, the structure of ECM 
around DRs depends on the injury and regeneration program [96]. Moreover, 
the amount of ECM at various parts of single DR can differ greatly. For 
example, a fibrotic liver in a patient with alcoholic liver disease shows dense 
collagen deposition around biliary ends of the DR, but very little collagen 
around hepatocytic ends [120], meaning that cells with thin layer of ECM are 
exposed to different signaling molecules and factors than those embedded in 
thick ECM, which in turn may lead to different differentiation pathways. That 
could, to some extent, explain the cellular diversity within DR in terms of 
morphology and immunophenotype, as it has been shown that hepatocyte-like 
progenitors are mostly at the parenchymal border of DRs, and cholagiocyte-like 
cells at the portal border [48].   
Although collagen has an important role in DR niche and is prominently 
expressed in fibrotic liver tissue, it is not the only ECM component that has an 
active influence on progenitor cell behaviour. Ductular reactions are also 
surrounded by laminin matrix [93]. In fact, progenitors need contact with 
laminins in the basement membrane in order to maintain their progenitor/biliary 
state; and laminin deposition is essential for DR expansion and for the in-
hibition of hepatocytic differentiation [41, 120, 121]. By contrast, suppressing 
laminin production yields less DRs and induces differentiation toward hepato-
cytes [41]. In a low dose of acetylaminofluorene (AAF)/ PH rat model, when 
progenitor cells lose contact with basement membrane (starting from the distal 
end of the DR), they simultaneously begin differentiating toward hepatocytes 
[122]. In addition, in alcoholic hepatitis, a disease with prominent laminin 
deposition, only biliary differentiation is observed [123]. In vitro studies have 
demonstrated that liver progenitor cells preserve their progenitor markers, up-
regulate cholangiocyte specific genes, and down-regulate hepatocyte-specific 
gene C/EBPα when cultured on laminin but not on collagen I, IV, or fibronectin 
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(FN) [93]. On the contrary, FN matrix was shown to induce hepatocyte gene 
expression and differentiation toward hepatocytes [93], indicating that FN may 
be involved in hepatocyte fate determination.  
Thus far, 16 laminin trimers have been identified [124] and not all laminins 
have the same effect on stem cells. For example, while laminin-511 supports the 
self-renewal and undifferentiated state of human and mouse embryonic stem 
cells, laminins-111, -332, and -411 do not have same competence [125, 126]. 
Laminin-322 has been shown to mediate osteogenic differentiation of mesen-
chymal stem cells [127], whereas laminin-111 induces neural fate [128]. Not 
much is known about different types of laminins and their roles in adult liver. 
Laminins-511 and-521 are expressed in normal liver while laminin-111 is 
transiently expressed after PH [129]. Laminin composition in chronic liver 
injury has not been extensively studied.  
 
 
2.8. Liver progenitor cells and tumor development 
Liver cancer is one of the most common cancers worldwide. Two types of 
primary liver cancers are hepatocellular carcinoma (HCC) and cholangio-
carcinoma (CC). 80% of HCCs develop after long and persistent chronic liver 
injury, whereas CCs have an agressive nature and are often discovered in late 
stages [130]. There are many different risk factors associated with liver malig-
nancies, such as hepatitis virus B and C, alcohol, diabetes, obesity, toxins, para-
sitic infections, hereditary conditions,  etc. [131, 132], which could explain the 
high heterogeneity of liver cancers. HCCs are presumed to originate from 
hepatocytes and CCs from biliary epithelial cells, however, bipotential liver 
progenitor cells are also considered as possible contributors. The hypothesis of 
a common ancestor is supported by the fact that liver tumors often contain cells 
with heterogenous morphology, mixed immunophenotype of biliary and hepato-
cellular features, and a side population with progenitor cell profile [48, 133]. 
Even pure HCCs contain subpopulation of small cells with progenitor cell 
markers EpCAM, CK19, and AFP [134, 135]. Whether these intratumoral 
progenitors can be regarded as cancer stem cells is still an open question. 
However, hepatitis virus C patients with EpCAM+CK7+CK19+ intermediate 
cell foci in liver biopsies have been shown to possess higher risk of developing 
liver cancer [136], and overall CK19 expression in HCCs is associated with 
worse prognosis, higher rate of metastasis and cancer recurrence after liver 
transplantation [137]. Transdifferentiation is another possible mechanism for 
liver tumor development. Although CCs are presumed to arise from cholangio-
cytes or, possibly, liver progenitor cells, hepatocyte-specific lineage-tracing 
experiments by two independent groups have demonstarted that CCs could 
alternatively originate from mature hepatocytes through Notch-mediated trans-
differentiation and AKT-mediated neoplasia [64, 138]. Considering the hetero-
geneity of liver tumors, it is reasonable to speculate that primary liver cancers 
could be derived from multiple sources. 
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2.9. Overview of AKT signaling pathway  
AKT (also called protein kinase B, PKB) is a serine/threonine kinase involved 
in diverse processes, including cell survival, proliferation, and metabolism. 
AKT family members AKT1/PKBα, AKT2/PKBβ, and AKT3/PKBγ are highly 
homologous despite being encoded by different genes on different chromo-
somes, and have overlapping or distinct functions, depending on the cellular 
context [139]. AKT is the central component in a pathway comprised of a 
myriad of proteins, some of which are tumor suppressors (eg. PTEN, FOXO) 
and others act as oncoproteins when overexpressed or activated (eg. eIF4E, 
PI3K) [140]. Hyperactivated AKT signaling has been associated with many 
diseases and malignancies in various tissues, underlining the importance of tight 
regulation of AKT activity in normal cell functioning [139]. In normal cells, 
AKT is maintained in an inactive unphosphorylated state [141]. Upon phospho-
rylation at Thr308 by PDPK1 (3-phosphoinositide-dependent protein kinase 1) 
AKT becomes active, however, for full activity phosphorylation at Ser473 is 
also required [141, 142]. A number of growth factors (GF) (eg. hepatic GF, 
insulin-like GF, fibroblast GF, nerve GF), cytokines, and stress stimuli (eg. 
hypoxia, heat shock, DNA damage, reactive oxygen species) are known to 
trigger AKT activation and subsequent translocation to different subcellular 
compartments, where it exerts its biological functions [143]. Depending on the 
stimulus, location, isotype, and context the activated AKT can induce cell cycle 
progression, proliferation and cell migration, as well as inhibit apoptosis, and 
control different metabolic processes [139, 140, 143].  
 
 
2.9.1. AKT signaling pathway in liver diseases 
In the liver, AKT not only participates in its normal functioning, but is also 
activated in response to cytokines and GFs released after tissue loss. AKT 
signaling pathway is believed to control liver regeneration by inducing the 
hepatocytes to move from quiescent state to proliferative state and by regulating 
the process of hepatocyte hypertrophy [144, 145]. As AKT is involved in 
glycose and lipid metabolism in the liver, dysregulated AKT is implicated in 
several metabolic liver disorders. For example, insulin resistance and type 2 
diabetes are accompanied by abnormally low AKT levels [146], whereas hyper-
activated PI3K/AKT/mammalian target of rapamycin (mTOR) pathway is 
detected in fatty liver diseases and liver cancer [147, 148]. Nearly 40% of HCCs 
show elevated AKT2 levels [149], while active phosphorylated mTOR 
(pmTOR) is present in 15% of HCCs [150]. The levels of pmTOR and pAKT 
are also in a positive correlation with the expression of potential hepatic cancer 
stem cell markers CD133, CD90, and EpCAM [151]. Moreover, CD133+ HCC 
cancer stem cells with active pAKT are more resistant to chemotherapy 
compared to the tumor cells that lack CD133 [152], underlining the positive 
effect of AKT activation on cell survival. Hyperactivated PI3K/AKT/mTOR 
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pathway participates in tumor ECM remodeling by up-regulating the expression 
of MMP-9, a common cancer MMP involved in matrix degradation [153]. Since 
rearrangement of ECM is necessary for tumor cell invasion and metastasis, it is 
not surprising that activated AKT is also linked with enhanced invasiveness of 
cancer cells [154, 155]. On the other hand, the expression of PTEN, the inhi-
bitor of AKT pathway, is reduced in 40% of HCCs [156] as are the levels of 
many proapoptotic AKT targets, such as BID, BAX, and P53 [143]. Since AKT 
activation and the results of aberrant AKT signaling are considered a common 
hallmark of cancer, components of this pathway have become attractive targets 
in anticancer drug design [140].  
 
 
2.10. Dupuytrenʼs contracture 
Dupuytrenʼs contracture (DC) is a progressive and irreversible fibrotic disease 
characterized by uncontrolled myofibroblast proliferation and formation of 
contractile nodules and collagen-rich cords in the palm of the hand [157], which 
cause bending of fingers (usually the forth and fifth digits) and gradual 
reduction in hand function.  
DC occurs in three stages: proliferative phase, involutional phase, and 
residual phase [158]. The proliferative phase of DC is characterized by the 
proliferation of myofibroblasts and formation of nodules. In the involutional 
phase the disease advances, myofibroblasts align along the palmar fascia, 
resulting in the development of the cord and deposition of type III collagen. In 
the residual phase the myofibroblasts and nodules begin to disappear while the 
disease spreads further into fingers, the fibrous cords tighten and fingers 
contract towards the palm [159].  
Surgical removal of the diseased tissue is the most common DC treatment 
method, however, surgery has several side effects and the recurrence for DC is 
quite common [160]. DC is most prevalent in Caucasian men of Northern 
European ancestry, and although the cause of this condition is not known, DC 
has been associated with alcoholism, diabetes mellitus, epilepsy, manual labor, 
smoking, and trauma [161]. A recent twin study showed that genetic factors 
play a major role in DC development, however, no particular genes have been 
confirmed to be responsible for DC [162].  
Fibrosis is a pathological condition that can affect various tissues, including 
the liver, lungs, skin, kidneys, and cardiovascular system [163]. In DC, simi-
larly to other fibrotic diseases, the excessive ECM (mostly collagens and fibro-
nectins) is produced by increased number of myofibroblasts [158, 164]. It has 
been shown that proinflammatory cytokines such as tumor necrosis factor 
(TNF) [164], profibrotic cytokines such as TGF-β, and growth factors such as 
basic FGF (bFGF) [165–167], which are upregulated in DC tissue, induce 
proliferation and/or differentiation of myofibroblasts. Higher fibroblast density 
could explain increased collagen III/I ratio in DC, as it has been demonstrated 
that collagen I production is inhibited at high fibroblast concentration [168]. 
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Inhibition of MMPs could also play a role in matrix deposition in DC. Indeed, a 
genome-wide analysis identified three MMPs – MMP1, MMP3, and MMP16 – 
that were significantly downregulated in fibroblasts derived from DC tissue 
[169]. There are several other modulators and pathways such as AKT and Wnt 
signaling pathways [169] that are implicated in DC pathogenesis, however, 
there is no overall consensus regarding the exact mechanism that is responsible 
for the onset and progression of this disease. The data gathered so far suggest 
that it is a combination of dysregulated cytokine and growth factor signaling 
along with altered ECM composition that induces and sustains DC progression.  
  
27 
3. AIMS OF THE STUDY 
The aims of the study were as follows: 
1.  To identify, locate, and characterize quiescent liver LRCs, and determine 
their contribution in liver homeostasis and regeneration. 
2.  To identify the changes in the liver ECM after liver injury, and study the 
impact of these changes on cell proliferation. 
3.  To characterize the composition of ECM in Dupuytrenʼs disease, and study 
the molecular mechanisms promoting the progression of this disease. 
4.  To identify the inhibitor of AKT1-PDPK1interaction and study its possible 
antitumor properties. 
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4. RESULTS AND DISCUSSION 
4.1. The LRC identification strategy (Ref I)  
In the LRC assay, slowly cycling cells are distinguished from rapidly proli-
ferating cells by their ability to retain nuclear label. In the past, the identifi-
cation of quiescent label-retaining adult liver stem cells has based on the in-
corporation of BrdU into DNA. This strategy, however, requires active DNA 
synthesis, which is in sharp contrast to the basic nature of quiescent stem cells. 
A way to force stem cells exit quiescence is to induce injury, an approach which 
has been used to label cells with BrdU in the liver. As the regeneration 
mechanism in the liver depends on the specific injury, the progenitor response 
can vary greatly between injuries, and generally the activation of differentiated 
cells and/or infiltration of extrahepatic cells is also involved. Therefore, cell 
labeling coupled with injury may not be the best method for identifying resident 
stem cells in the liver. On top of that, treatments required for BrdU visualization 
do not allow live cell isolation for further investigation. 
Development of new genetic tools has made it possible to identify LRCs in 
uninjured liver. To locate quiescent liver stem cells in normal physiological 
conditions we used a bitransgenic mouse model in a pulse-chase experiment 
that enabled us to first, label liver cells in neonatal mice, then, monitor label 
retention and characterize LRCs in adult mice, and finally, study isolated cells 
in vitro. Bitransgenic mice were generated by crossing mice, which express 
histone H2B-enhanced green fluorescent protein (H2B-EGFP) under the control 
of doxycycline (dox) inducible tetracycline regulatory element (TRE) [170] 
with a mouse line harboring Rosa 26 promoter-driven reverse tetracycline-
dependent transactivator transgene (R26-rtTA) [171] (Fig. 1a). When the 
offspring of this mating received dox from birth to postnatal day 5 (P5), 86% of 
CK19+ cholangiocytes and 98% of HNF4α+ hepatocytes expressed H2B-EGFP 
fusion protein on P5 (Fig. 1b,e). Such high level of transgene induction at the 
beginning of the experiment confirmed its suitability for LRC identification in 
subsequent chase phase. We administered dox straight after birth because we 
reasoned that massive liver growth and high proliferative activity in adolescent 
mice would induce rapid EGFP dilution, and we would be able to distinguish 
LRCs from the background much quicker, as opposed to adult mice in which 
liver cells proliferate infrequently (Suppl. Fig. 1a-b).  
 
 
4.2. Identification of liver LRCs (LLRCs) (Ref I) 
After 1 week of chase (W2), there were no significant changes in the number of 
H2B-EGFP expressing cells (Fig. 1e). There are two explanations for this 
phenomenon: first, although cells are highly proliferative at this stage of liver 
development, it is possible that dox was still being washed out from the system 
and transgene was induced in newly formed cells by residual dox. And second, 
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we could detect somewhat lower EGFP intensity at W2 when compared to P5 
(Fig. 1d, Suppl. Fig 2b), indicating cell proliferation and EGFP dilution even if 
it was not accompanied by smaller EGFP+ cell numbers. A significant drop in 
EGFP intensity was seen at W3 (Fig. 1d, Suppl. Fig. 2a-b), but yet again the 
proportion of labeled CK19-positive cholangiocytes was not decreased and the 
percentage of HNF4α-positive hepatocytes was decreased by 8% (Fig. 1e). A 
significant change occurred at W7 when, for the first time, we could distinguish 
LRCs in bile duct-like structures from the background (Fig. 1d, Suppl. Fig. 2a-
b), as the majority of hepatocytes had lost their labeling (decrease from 90% to 
3%), whereas the majority of cholangiocytes had retained the label (from 86% 
to 71%) (Fig. 1e). From W7 to W15 the number of labeled hepatocytes conti-
nued to decrease (Fig. 1e) until only single EGFP+ hepatocytes could be found. 
In the cholangiocyte compartment, however, the EGFP positive cell population 
maintained its size, and we concluded that in the normal liver the LRCs reside 
in the bile ducts. Since the proliferation kinetics profile among cholangiocytes 
and hepatocytes was quite similar (Suppl. Fig. 1c-d), there are several possible 
scenarios that could explain how the biliary cells retain the EGFP label. One 
can speculate that while all hepatocytes divided during the chase period and 
thereby lost the label, in cholangiocyte compartment only a subset of cells 
proliferated repeatedly and the remaining cells stayed quiescent or divided less 
frequently. The other explanation is based on the “immortal DNA strand hypo-
thesis”, which proposes that in a certain type of asymmetric cell division 
chromatids are segregated between daughter cells according to the age of the 
template [172]. Older chromatids are sorted to the cell that becomes the stem 
cell and newly synthesized chromatids are sorted to the second daughter cell 
that is destined to differentiate. The existence of nonrandom template strand 
segregation has been demonstrated in intestinal [173], muscle [174], and neural 
stem cells [175]. In the liver, however, it appears that label retention is 
achieved, at least to some extent, by differential proliferation activity among 
biliary cells. We compared Ki67 expression in EGFP+ and EGFP- biliary cells 
and found that although EGFP+ cells proliferated actively in neonatal mice, 
their proliferative activity declined sharply at week 2 and remained lower than 
that of EGFP- cells until the end of the chase period (Suppl. Fig 3c). It has to be 
noted that changes in EGFP-H2B expression cannot be attributed solely to DNA 
duplication since a subset of H2B histones is also removed from nucleosome 
when replication is not present [176]. 
 
 
4.3. Characterization of LLRCs (Ref I) 
4.3.1. LLRC immunophenotype 
Potential bile duct-associated hepatic progenitors and bile duct cells share 
several common antigens [49]. As we had established that LLRCs in adult mice 
localized in the bile ducts, our next goal was to characterize LLRCs using 
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antibodies, which recognize biliary cells and which have been used in pro-
genitor cell characterization. We found that in addition to CK19, LRCs also 
express EpCAM, CD133, increased levels of CD166, and A6 (Fig. 2c-f, Suppl. 
Fig. 5a-d). The parenchyma was essentially EGFP-negative with rare labeled 
hepatocytes (Fig. 2b). These results confirmed the biliary status of LRCs and 
provided us with a selection of cell surface antigens (EpCAM, CD133, CD166) 
that could be used for live cell isolation in later stages.  
 
 
4.3.2. LLRC response to liver damage and  
participation in regeneration 
4.3.2.1. LLRC are not activated in hepatocyte injury 
The reparation mechanism that drives liver regeneration following injury is 
thought to be dependent on the type of injury. We used five different mouse 
models of liver injury to study the contribution of LLRCs in regeneration (Fig. 
3). We found that in response to acute hepatocyte injury by single CCl4 
injection the LLRC compartment was not activated as the proliferative activity 
of EGFP+CK19+ cells remained at maintenance level (Fig. 4a,d) and there was 
no decrease in labeled cholangiocyte number after 2 weeks of recovery (Fig. 
3b,g). To induce massive hepatocyte regeneration without hepatic toxins we 
performed 2/3 partial hepatectomy and again observed that the number of 
biliary LRCs remained essentially unaltered (Fig. 3c,g). A slight, yet statis-
tically insignificant tendency toward decrease could be explained by the fact 
that not only hepatocytes but also other mature liver cell types proliferate after 
PH [177]. Since DRs are not induced after PH and previous studies have also 
shown that stem cell activation does not occur in this type of regeneration [177], 
it is unlikely that the LRCs, which lost their label during recovery, gave rise to 
new hepatocytes. Based on these observations we concluded that LLRCs are not 
needed for hepatocyte regeneration when hepatocytes are capable of re-es-
tablishing tissue homeostasis. Therefore, it would be interesting to study the 
behavior of LRCs in a situation where hepatocyte proliferation is suppressed. 
Indeed, several studies indicate that liver progenitors are activated in response 
to hepatolobular damage only when hepatocyte proliferation is compromised. In 
rats, this can be achieved by combining 2-acetylaminofluorene (2-AAF) admi-
nistration with PH [178] or CCl4 [179]. Both of these liver injury models have 
been shown to stimulate the expansion of oval cells, however, their contribution 
to hepatocyte regeneration and restoration of liver function has remained 
controversial [122, 180]. To block hepatocyte proliferation in mice a transgenic 
mouse model of Damaged DNA Binding protein 1 (DDB1) selectively deleted 
in hepatocytes has been generated. DDB1 deletion was shown to abolish 
hepatocyte self-renewal capacity which led to DR expansion and their differen-
tiation toward hepatocytes [181].  
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4.3.2.2. LLRC are induced to proliferate in response  
to primary biliary injury 
To study the behavior of LRCs in response to biliary injury, we either per-
formed total bile duct ligation (tBDL), or fed the mice DDC or CDE diet. tBDL, 
DDC and CDE diet target not only cholangiocytes but other liver cell types as 
well. These widely used injury models mimic a variety of human liver diseases, 
including secondary biliary fibrosis, alcoholic and nonalcoholic steatohepatitis, 
metabolic liver diseases, sclerosing cholangitis, biliary fibrosis, and chronic 
cholestatic liver diseases [182]. Although no known mouse model corresponds 
exactly to specific disease, they are a valuable tool for understanding the under-
lying mechanisms of liver disease development [182]. tBDL, DDC and CDE 
diet all induced ductular reactions, infiltration of immune cells, and LRC acti-
vation. After DDC diet and tBDL, most bile ducts and DRs were EGFP nega-
tive (Fig. 3d-e) with only 6% and 10% of CK19-positive LRCs left, respectively 
(Fig. 3g), suggesting that these injuries induced LRC proliferation. Indeed, the 
expression of proliferation marker Ki67 was dramatically increased in the 
biliary compartment of injured livers when compared to low proliferation rate in 
normal adult livers (Fig. 4 b-d). Interestingly, in case of tBDL, the LLRCs pro-
liferated more actively than non-LRCs, indicating a difference in their responsi-
veness and proliferative capacity in certain injury conditions. Although CDE 
diet-induced biliary damage did not cause as dramatic decrease in LRCs num-
bers as tBDL or DDC, the change was still significant (Fig. 3g). A number of 
DRs in CDE liver demonstrated weak EGFP signal (Fig.3 f), suggesting that 
they were derived from biliary LRCs. Overall, these results demonstrated that 
the activation of LRCs is needed after biliary injury, LRCs proliferate, and 
thereby lose EGFP-labeling. 
In parallel with these observations, we noticed the appearance of CK19-
negative cells with strong EGFP signal around DRs (Fig. 3d-f, Fig. 4b-c). Since 
H2B-EGFP transgene has been shown to be promiscuously expressed in bone 
marrow by hematopoietic cells without dox induction [183], we hypothesized 
that these CK19-EGFP+ cells might be of hematpoietic origin infiltrating into 
the site of injury. Immunostaining with pan-leukocyte marker CD45 confirmed 
that these cells were indeed infiltrating inflammatory cells and not hepatic cells 
(Suppl. Fig. 6a). 
 
 
4.3.2.3. Differentiation potential of LLRCs 
Loss of EGFP expression in actively proliferating LRCs made it impossible to 
determine their differentiation potential in vivo, as we would not have been able 
to distinguish normal liver cells from LRC-derived cells. Therefore, in order to 
study their multipotency and self-renewal properties, we isolated live cells from 
normal pulse-chased mouse livers by fluorescence-activated cell sorting 
(FACS) (Fig. 6a) and cultivated them in vitro (Fig. 6b). The ability to self-
renew is a key feature of stem cells. To determine, whether liver LRCs possess 
32 
enhanced self-renewal capability, we compared the colony forming efficiency 
(CFE) of two biliary cell populations: EGFP+EpCAM+CD45- cells (LRCs) and 
EGFP-EpCAM+CD45-cells (non-LRCs). After two weeks of cultivation the 
LRCs formed colonies, whereas non-LRCs did not (Fig. 6d), suggesting that 
LRCs do indeed possess enhanced self-renewal capacity when compred to non-
LRC biliary cells. However, LRCs did not show bilineal differentiation poten-
tial, as we could only detect CK19 single-positive colonies devoid of any 
HNF4α-expressing hepatocytes (Fig. 6e-g). These data suggest that although 
LLRCs possess enhanced self-renewal capacity, they are restricted to biliary 
lineage.  
Our results corroborate with the study by Suzuki et al. where it was shown 
that although CD133+ biliary cells isolated from normal adult liver formed 
colonies, they did not differentiate into hepatocytes [54]. On the other hand, in a 
report by Okabe et al., it was shown that EpCAM+ cholaniocytes isolated from 
normal liver not only formed colonies as successfully as EpCAM+ cells  
isolated from DDC-injured liver (bile duct cells and DRs combined), but also 
differentiated into functional hepatocytes [40]. In this report, the differentiation 
was achieved by special differentiation medium, whereas we, and Suzuki et al. 
investigated “spontaneous” differentiation. One could argue that our unsuc-
cessful differentiation was caused by the lack of differentiating supplements in 
the medium. However, in the same Suzuki et al. report, it was demonstrated that 
CD133+ cells isolated from DDC-treated livers did possess bipotency even 
without supplemented medium.  
 
 
4.3.2.4. Gene expression profile of liver LRCs and non-LRCs 
We then compared the transcriptional profile of the aforementioned sorted cell 
populations by RNA sequencing in order to find out what are the molecular 
features that discriminate LLRCs from non-LRCs. We found that out of 95 
differently regulated genes, 20 were up-regulated and 75 down-regulated in 
LLRCs. Genes associated with tumorigenesis (Spdya, Styk1, Fgr, Pbk, Palb2, 
Cxcl10, Tmc7, Mas1) constituted almost half of the upregulated genes. This 
could be related to the enhanced self-renewal property of LLRCs we discovered 
previously. Interestingly, 5 of the upregulated genes are known to function in 
central nervous system but their function in liver is unknown. More than half of 
downregulated genes were related to plasma membrane or cell-cell contact 
formation. Several genes associated with vessel development (eg Wnt2, Bmp4, 
Rspo3, Flt1, Tek) [184] were also downregulated. The nature of downregulated 
genes suggests that LLRCs do not participate actively in the maintenance of 
biliary system in the normal liver. 
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4.4. Elucidating the contribution of biliary cells to liver 
maintenance and regeneration (Ref I) 
We had discovered that about 30% of biliary cells participated actively in post-
natal liver development and/or maintenance illustrated by the loss of EGFP 
label. At the same time, more than 70% of bile duct cells were quiescent or pro-
liferated fewer times, and thereby retained their label, but were strongly 
activated upon biliary injury. Although in vitro experiments suggested that 
LLRCs do not possess bipotency, we could not verify this in vivo with the R26-
rtTA-H2B-EGFP mouse model. Since LLRCs express CK19, we turned to a 
transgenic mouse model in which upon tamoxifen (TMX) injection the CK19 
positive biliary cells and their progeny start to express tdTomato (tdTom), 
allowing us to trace the fate of labelled cells in liver maintenance and regene-
ration. We injected mice with TMX at P21 and traced the tdTom label up to 6 
months (Fig. 5a-c). We found that during the homeostatic maintenance the 
CK19+ biliary cells give rise only to new biliary cells as we did not detect any 
other tdTom-labeled cell type with. To study the behavior of bile duct cells in 
liver regeneration we introduced 6 different types of liver injury and examined 
tdTom expression. tBDL, DDC diet, and CDE diet induced DRs, some of which 
were tdTom-positive, indicating that these cells originated from bile duct cells 
(Fig. 5d-f). As expected, not all DRs were tdTom-positive, since tdTom initial 
labeling efficiency in these experiments was much lower than 100%. However, 
we could not find any tdTom-labeled hepatocytes in these livers. We also did 
not detect any contribution from CK19+ compartment to hepatocyte recovery 
after PH (Fig. 5g), after short-term hepatocyte damage by single CCl4 injection 
(Fig. 5h), or after long-term hepatocyte damage by repeated CCl4 administration 
(Fig. 5i). Based on these results and data from H2B-EGFP mouse experiments, 
we concluded that LRCs in an adult liver represent a population of fully diffe-
rentiated cells, which, compared to other biliary cells, have retained superior 
regenerative capacity due to overall lower proliferative activity during liver 
postnatal development and maintenance. Despite their enhanced self-renewal 
property, LLRCs have restricted differentiation potential and only take part in 
biliary cell regeneration. 
  
 
4.5. Changes in liver ECM after liver damage (Ref II) 
Liver regeneration involves not only cell proliferation but also remodeling of 
extracellular matrix [185]. As the components of ECM facilitate signal trans-
duction between cells and their environment, rearrangements in ECM cause 
shifts in cell signaling which in turn lead to necessary changes in cell behavior. 
The correct ECM composition during liver tissue repair is achieved by coordi-
nated balance between protein synthesis and degradation [186, 187]. Since dys-
regulated ECM production and degradation is implicated in many liver patho-
logies [187], knowledge about the changes in ECM and the molecular 
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mechanisms behind them could be used for the prevention and treatment of 
liver diseases. 
 
 
4.5.1. ECM protein composition after liver injury 
In order to study how acute CCl4 injury and DDC-induced injury change liver 
ECM composition, we first decellularized and homogenized the liver samples, 
then performed proteomics analysis using nano-LC-MS/MS, and finally com-
pared the protein contents of normal and damaged liver samples (Fig. 1A). We 
found that the levels of 32 ECM proteins were altered in CCl4-treated livers 
(48h after injection), the levels of 22 proteins were altered in DDC-treated livers 
(fed for 2 weeks), and only 9 proteins were similarly up-or downregulated in 
response to both treatments (Fig. 1B), indicating that regeneration from 
different types of liver injuries required different ECM composition. Indeed, 
while DDC induced upregulation of collagen I and V and downregulation of 
collagen VI, in CCl4 treated livers we detected significant downregulation of 
collagen IV and VIII (Fig. 1C). Upregulation of collagen I mRNA in DDC-
treated liver has been shown before [188]. Deposition of FN and down-
regulation of laminin chains α3, α5, and γ2 was detected in both liver injuries. 
Since CCl4 is specifically toxic to hepatocytes it was no surprise that FN was 
up-regulated following CCl4 treatment as FN has been shown to be necessary 
for hepatocyte survival in acute liver injury [189]. Antiapoptotic FN properties 
have been described also for ovarian and breast cancer cells, where adhesion to 
FN activated PI3K/AKT2 pathway, which ultimately led to chemoresistance of 
the tumor cells [190]. In addition, FN is also known to control the availability of 
active TGF-β in injured liver [191]. Imbalanced TGF-β signaling leads to 
enhanced stellate cell activation and fibrosis, whereas FN up-regulation pre-
vents TGF-β overactivation and protects liver from excessive fibrosis [191], 
thereby giving the liver time to regenerate. In conclusion, FN deposition 
appears to have protective role in liver injury. 
 In addition to the changes in the composition of structural ECM proteins, we 
also identified several non-structural ECM components, which were deregulated 
in response to liver injury (Fig. 1C). CCl4 injury induced up-and downregulation 
of numerous proteins, whereas DDC diet influenced the levels of only a few 
non-structural ECM proteins, indicating that different pathways or mechanisms 
might be involved in liver regeneration after these two injuries. 
 
 
4.5.2. The changes in the elasticity and  
microarchitecture of ECM after liver injury  
Elastin is usually accumulated in fibrotic and cirrhotic livers [192, 193] and is 
used as a marker to describe the chronicity of fibrotic change [194]. Although 
DDC diet is known to induce biliary fibrosis [195], we did not detect higher 
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elastin levels in the livers of DDC-fed mice. It is possible that 2-weeks of DDC 
feeding was not long enough to induce substantial fibrosis, as elastin deposition 
occurs only in the advanced stages of fibrosis [193]. In acute CCl4 injury, the 
level of elastin was significantly decreased (Fig. 1C). Since elastin provides 
flexibility to the liver ECM, we hypothesized that CCl4-treated livers would be 
stiffer than normal livers. We measured the stiffness of decellularized livers 
with atomic force microscope (AFM) indentation and found that, indeed, the 
ECMs isolated from the CCl4-treated livers were significantly stiffer than ECMs 
of normal livers, whereas DDC-treated livers showed only slight increase in 
liver stiffness (Fig. 3G). Increasing evidence suggest that contact with stiffer 
matrix may facilitate activation of hepatic stellate cells and portal fibroblasts, 
and induce proliferation of active myofibroblasts [196]. In case of acute liver 
injury this activation would be short-term but in persistent injury conditions 
active myofibroblasts would produce increasing amounts of matrix proteins, 
which eventually would lead to fibrosis. This could explain why the increased 
liver stiffness precedes matrix accumulation and fibrosis [197].  
Both liver injuries also induced remarkable disorganization of the ECM 
structure. In normal liver, the collagen was organized in wavy cords or tape 
shape fibers (Fig. 3A-B), whereas in injured livers we detected disarranged and 
branched reticular-type collagen fibers (Fig. 3C-F). Such dramatic changes in 
the ECM architecture suggest that the changes in its molecular makeup might 
play a part in this process. Since ECM stores numerous cytokines, growth 
factors, hormones, and enzymes, changes in its structure are likely to influence 
their availability. Altered composition, concentration, or activation of signaling 
molecules is a common feature in injured liver. The exact role of the structural 
alterations of the ECM in liver regeneration and disease, however, are yet to be 
determined. 
 
 
4.5.3. Impact of structural ECM components on  
cholangiocyte and hepatocyte proliferation 
Proteomics analysis provided us the information about the overall changes in 
ECM composition in response to liver injury. In order to determine the exact 
location of these changes in the liver, we performed immunofluorescence 
analysis and studied the expression and localization of structural ECM compo-
nents in the livers of CCl4-and DDC-treated mice (Fig. 2). FN was accumulated 
around portal areas and sinusoids in both damaged liver samples. In DDC-
treated livers, collagen I and IV accumulated periportally, whereas in CCl4-
treated livers, we detected collagen I accumulation pericentrally and collagen 
IV reduction in pericentral sinusoids. We also studied the expression of 
proliferation marker Ki67 and found that proliferating cells concentrated around 
portal areas (Fig. 5C). Immunostaining results are discussed further in the 
context of the data from in vitro experiments in the next paragraph.  
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Since CCl4 intoxication and DDC diet primarily affect different cell popu-
lations, and the respective changes in ECM composition according to proteo-
mics analysis were different to a large extent, we hypothesized that individual 
ECM components may have different effect on hepatocytes and cholangiocytes. 
We isolated hepatocyte and cholangiocyte populations from normal livers and 
cultured them on dishes coated with FN, collagen I, or collagen IV. We found 
that FN and collagen I, which were up-regulated in DDC-treated mice, pro-
moted the growth and proliferation of biliary cells more effectively than 
collagen IV (Fig. 4A-C). This is in good correlation with the findings that in 
DDC-treated liver, FN and collagen I accumulated around biliary ducts and 
ductular reactions, where the proliferative activity is the highest.  
In contrast, the proliferation of hepatocytes was most prominent on collagen 
IV (Fig. 5A-B). Although the overall collagen IV expression was down-
regulated in CCl4-treated livers, its expression was retained at normal level 
around portal areas where the proliferative hepatocytes were located (Fig. 5C), 
correlating well with the results obtained in in vitro experiments.  
Although FN was upregulated in CCl4-treated livers, it had only a modest 
impact on hepatocyte proliferation. It has been shown previously that while FN 
helps hepatocytes to evade apoptosis it is not necessary for their proliferation 
[189]. In addition, FN plays an important role in regulating cell-to-cell and cell-
to-matrix adhesion [198]. Since FN accumulated in the portal areas where new 
hepatocytes were generated, it is possible that in addition to facilitating pro-
survival signals, FN enhanced the establishment of interactions between newly 
formed hepatocytes and neighboring cells and the ECM.  
Results from in vitro experiments, immunofluorescence analysis, and proteo-
mics analysis suggest that hepatocytes and cholangiocytes require specific niche 
composition for cell proliferation.  
 
 
4.6. Molecular mechanisms that regulate cell proliferation 
in Dupuytrenʼs contracture (Ref III) 
Dupuytrenʼs contracture is a widespread disease affecting both men and wo-
men, and although it has been extensively studied since its first description 3–4 
centuries ago [199], the knowledge regarding DC pathogenesis is fragmented 
and the molecular mechanisms involved in DC pathogenesis are still poorly 
understood. Since DC is characterized by increased myofibroblast proliferation 
[158], our goal was to identify the molecular and structural components that 
support this process. 
In order to study the molecular and cellular mechanisms sustaining the 
fibrotic processes in DC, we utilized immunofluorescence analysis and quanti-
tative PCR (qPCR) methods and compared the gene and protein expression 
profiles of DC and normal palmar fascia (NPF) samples. First, we determined 
that the majority of proliferating cells in DC were smooth muscle actin (SMA)-
positive myofibroblasts located in or in the vicinity of the blood vessels, which 
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were abundantly scattered throughout the DC tissue (Fig. 1a-f). A small pro-
portion of proliferative endothelial cells indicated the formation of new blood 
vessels (Fig. 1f). Blood vessels in NPF samples were very rare and they did not 
contain proliferating cells (Suppl. Fig. S1a,c). Increased vascularisation in DC 
also caused higher ECM content in DC tissue samples, as laminins 411/421, 
511/521, and collagen IV (components of the endothelial basement membrane 
[200]) and SMA were expressed in myofibroblast layer of the blood vessels 
(Suppl. Fig. S1b,d;S2,S3). Although we detected FN in both NPF and DC 
tissues, increased amounts of FN were expressed in blood vessel walls in 
diseased tissue (Suppl. Fig. S3n-p).  
Angiogenesis is an important component in wound healing and a stimulator 
of fibrosis in several tissues [201]. Furthermore, it has been previously shown 
that stem cell niches in normal [202] and malignant [203] brain tissues, and in 
heart [204] contain small blood vessels that regulate stem cell self-renewal. As 
we had found that the majority of proliferative cells concentrated in and around 
blood vessels, we hypothesized that blood vessels could possess similar role in 
DC and thus maintain the uncontrolled cell proliferation. Since AKT signaling 
pathway has been proposed to play a role in DC [205] and AKT hyperactivation 
can cause abnormally high cell proliferation [140], we studied phosphorylated 
AKT (pAKT) presence in the blood vessels of DC and NPF samples. We 
detected pAKT in all the layers of blood vessels in DC tissues (Fig. 3a). Interes-
tingly, in addition to blood vessels, pAKT was highly expressed in sweat gland 
ducts and acini (Fig. 3b).   
Next we studied the protein and mRNA expression of growth factors that 
have been associated with DC development. These include pro-proliferative 
growth factors bFGF and insulin-like growth factor-2 (IGF-2) [167, 206], and 
pro-fibrotic connective tissue growth factor (CTGF) [207]. CTGF is a TGF-β 
downstream modulator involved in extracellular matrix synthesis [208]. CTGF 
is known to exert fibrotic activity in other tissues, as well. For example, CTGF 
mRNA is significantly upregulated in fibrotic and cirrhotic livers [209, 210]. 
Likewise, bFGF expression levels are also elevated in fibrotic livers [211], and 
increased IGF-2 expression have been reported in livers with fibrosis and HCC 
[212]. As expected, all three were up-regulated in DC tissues (Fig. 3d-f), 
however, each growth factor exhibited unique expression pattern. IGF-2 was 
expressed throughout the DC tissue (Fig. 3j-k). IGF-2 is known to induce cellu-
lar contractility in DC [206], which could explain its homogenous expression. 
bFGF was expressed in blood vessel endothelium (Fig. 3m-n), while CTGF was 
detected in sweat gland acini (Fig.3 g-h). The role of sweat glands in DC 
development is unknown, however, the expression of pAKT in ducts and acini, 
and CTGF presence in acini suggests their involvement in DC pathogenesis. 
Overall, these results suggest that DC progression involves upregulation of 
growth factors that are also implicated in other fibrotic diseases. We propose 
that CTGF originating from sweat glands, bFGF secreted from blood vessels, 
and IGF-2 released from ECM synergistically induce the upregulation of AKT 
pathway. Increased AKT signaling in conjunction with the specific ECM 
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composition forms an environment near the blood vessels that supports 
myofibroblast proliferation and pathologic ECM production. At the moment, 
hand surgery is the prominent treatment for this disease. Inhibition of growth 
factor-induced AKT pathway might represent a new therapeutic strategy in DC 
treatment when less invasive methods are needed. Since these molecules are 
also overexpressed in other fibrotic and malignant diseases, similar approach 
could be considered for several diseases.    
 
  
4.7. Identification of small-molecule inhibitors of  
AKT1-PDPK1 interaction (Ref IV) 
AKT signaling is aberrantly upregulated in many different diseases and tumors 
[139]. Although there are a number of inhibitors that target AKT pathway 
[213], they exert broader kinase specificity and are thus relatively toxic, which 
prevents their clinical usage. Since AKT is activated through phosphorylation of 
Thr308 by PDPK1 that physically interacts with AKT protein [141], we aimed 
at finding the inhibitors of AKT pathway that target this interaction. For this 
purpose we used split Renilla luciferase (Rluc)-based protein complementation 
assay (PCA) [214]. First, we generated AKT1 and PDPK1 fusion proteins with 
complementary Rluc fragments. When these fusion proteins were expressed in 
cells their interaction was detected as Rluc activity. When this interaction was 
interrupted the Rluc fragments moved apart and the enzyme activity dis-
appeared (Fig. 1A). We screened the NCI Diversity Set I small molecular 
compound library that contained 2000 chemicals, utilizing the PCA assay, and 
selected 36 chemicals for further evaluations (Fig. 1B). All 36 reduced AKT1-
PDPK1 interaction by at least 50 % (Suppl. Table S5), but their toxicity stayed 
below 25 %.  
In the following step we tested the ability of the selected chemicals to reduce 
AKT1 phosphorylation at Thr308 by western blot (Fig. 2A). We found that out 
of 36 chemicals only 4 significantly reduced AKT1 phosphorylation while 
having no effect on cell density and morphology (Suppl. Fig.S1A-D).  
Next, we utilized in situ proximity ligation assay (PLA) to study the potency 
of the selected 4 compounds to disrupt the interaction between endogenous 
AKT1 and PDPK1 proteins in PC-3 prostate cancer cells with active AKT 
signaling pathway. We found that only one compound, NSC156529, inhibited 
this interaction (Suppl Fig. S2), as the number of AKT1-PDPK1 interaction 
sites was significantly decreased in cells incubated with NSC156529 compound 
when compared to control cells.  
Treating cells with NSC156529 compound also inhibited AKT downstream 
anti-apoptotic and pro-proliferative targets such as pBAD, pGSK3β, pFOXO, 
and phosphorylated procaspase 9 (Fig. 3B). The anti-proliferative effect of 
NSC156529 was further illustrated by its ability to inhibit cell growth of 
malignant and normal cells in vitro. We detected dose-dependent cell growth 
inhibition of PC-3 prostate tumor cells, osteoblasts, and fibroblasts (Fig. 3C). 
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NSC156529 inhibited also cell growth of HEK293, HepG2, K07074, and 
H1299 cell lines (Suppl. Fig. S4 A-D). 
In order to test the anti-proliferative properties of NSC156529 in vivo, we 
first established tumors in nude mice by injecting PC-3-EGFP prostate cancer 
cells under the dorsal skin of immunodeficient mice. When tumor size reached 
29–32 mm3 we proceeded with subcutaneous NSC156529 administration at 
concentrations 1 mg/kg, 5 mg/kg, or 10 mg/kg 3 times per week for 4 weeks 
(Fig. 4A). Control tumors were treated with vehicle only. We found that all 
NSC156529 concentrations inhibited tumor growth as measured with external 
caliper and an in vivo imaging device (Fig. 4B-C), and no adverse side effects 
such as weight loss or ulcerations were detected. We also measured alanine 
transaminase (ALT) and aspartate transaminase (AST) levels – indicators of 
liver damage – at the end of the experiment. We did not detect any significant 
increase, indicating that NSC156529 was not hepatotoxic (Suppl. Fig. S5). It 
has to be noted that while subcutaneous NSC156529 administration had no 
effect on mouse well-being, intraperitoneal administration caused severe 
irritation, suggesting a potential toxicity towards mucous membranes. 
Immunohistochemical examination of tumors showed lower pAKT and 
pBAD levels in NSC156529-treated tumors when compared to vehicle-treated 
tumors (Fig. 5A-B), indicating that NSC156529 inhibited AKT signaling in 
vivo. NSC156529-treated tumors were also mitotically less active than control 
tumors (presumably in consequence of decreased AKT activity) (Fig. 5C-D), 
but apoptotic activity in these tumors was not significantly increased (Suppl. 
Fig. S6A-B). Since apoptosis appeared not to be the mechanism behind tumor 
growth reduction, we hypothesized that treatment with NSC156529 induced 
differentiation of PC-3 tumor cells, which otherwise exhibit the properties of 
poorly differentiated prostate adenocarcinoma [215]. Indeed, we found that 
treated tumors showed increased expression of CK15/17 and CK8/18 – markers 
of fully differentiated prostate epithelial cells [216] – suggesting that the 
antitumor effects of NSC156529 are potentially mediated by tumor cell 
differentiation (Fig. 6). Whether this process is mediated by sole repression of 
AKT signaling remains to be verified. 
These results indicate that NSC156529 is a new small molecule compound 
that has potential in tumor treatment in different ways. For example, a 
combined therapy of pAKT inhibition by small molecule compound, followed 
by chemotherapy could be a possible treatment strategy for certain liver HCCs. 
It has been shown that liver HCCs contain stem cells harbouring active AKT 
signaling that makes them more resistant to chemotherapy [152] and can thus be 
the cause for cancer relapse. Hence, suppressing AKT activity before or during 
chemotherapy could potentially make the tumor stem cells more sensitive to 
chemotherapy. Furthermore, NSC156529 could be used to promote differen-
tiation in malignancies with undifferentiated cellular background that normally 
have poor response to conventional antitumor treatments. Currently, the most 
studied and clinically used differentiating agent is retinoic acid, which shows 
good results in acute promyelotic leukemia treatment, but has shown only 
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limited effect in the treatment of solid tumors [217]. Differentiating agents that 
have potential in solid tumors include histone deacetylase inhibitors trichostatin 
A, vorinostat and depsipeptide, and peroxisome proliferator-activated receptor-γ 
(PPARγ) agonist trogitazone [218]. These compounds have shown promising 
results in vitro but in clinical settings they have low effect on tumor size, or 
severe side effects when used as a single agent to treat solid tumors [219]. How-
ever, vorinostat administration in combination with other chemotherapy drugs 
has demonstrated anti-cancer activity in patients with head and neck cancer and 
non-small cell lung cancer [220], indicating that differentiating agents have 
potential in tumor treatment when used in a form of combined therapy.   
Since AKT pathway is also upregulated in fibrotic diseases, NSC156529 
could potentially be beneficial in fibrosis treatment. For example, inhibition of 
AKT1 has been shown to inhibit fibrosis in interstitial lung disease [221]. Taken 
together, the small molecular compound NSC156529 is a new promising 
candidate for the development of novel anti-tumor and possibly anti-fibrotic 
therapeutics. 
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5. CONCLUSIONS 
Most chronic liver diseases induce the accumulation of heterogenous cell popu-
lations – the ductular reactions. Although there is evidence that DRs are able to 
differentiate into cholangiocytes and hepatocytes, their origin is still under 
debate. It has been shown in other tissues that somatic stem cells are slowly 
cycling cells that can give rise to rapidly proliferating intermediate progenitor 
cells. We hypothesized that similar process could occur in the liver and there-
fore applied label-retaining cell assay to identify such cells in normal liver and 
study their behavior in liver injury. 
Any type of liver injury is usually accompanied by the deposition of extra-
cellular matrix. In case of chronic injury, ECM accumulates predominantly 
around DRs, forming a niche for regenerating cells. We studied in detail the 
ECM components that are up-or down-regulated in acute and chronic injury, 
and examined their effect on cell proliferation. 
Progressive deposition of ECM in chronic liver injuries that persist for 
several years leads to fibrosis, cirrhosis and in many instances to liver cancer. 
The pathological processes and signaling pathways that induce fibrosis are 
relatively similar in different tissues. Since the exact signaling network behind 
the fibrotic disease Dupuytrenʼs contracture had remained elusive, we studied 
the expression of some of the most important fibrosis-inducing components in 
DC tissue. 
AKT signaling pathway is upregulated in several fibrotic diseases and in 
many tumors, including liver tumors. Thus, AKT inhibition is a promising stra-
tegy in fibrosis treatment and in tumor therapy. Our goal was to find an inhi-
bitor of AKT1-PDPK1 interaction that would suppress AKT activity and tumor 
cell growth. 
The main results of this thesis can be outlined as follows: 
1.  In an adult liver, the slowly cycling cells, identified as label-retaining cells 
(LRCs), reside in the biliary duct system. ~ 70% of bile duct cells retained 
nuclear label for at least 15 weeks. 
2.  LRCs represent a population of fully differentiated bile duct cells that 
participate in biliary cell regeneration in response to chronic biliary liver 
damage, but are not activated in liver injuries, when primarily hepatocyte 
regeneration is needed. 
3.  LRCs possess enhanced self-renewal properties, nevertheless are restricted 
in their differentiation potential to biliary lineage in vitro.  
4.  Fully differentiated CK19-positive bile duct cells give rise to ductular 
reactions and new bile duct cells, but do not differentiate into hepatocytes in 
vivo. 
5.  The cell type which is predominantly affected in specific liver injury appears 
to dictate, at least partially, which alterations in the ECM composition occur 
in injured liver. And vice versa, distinct ECM components altered in injured 
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livers have diverging effects on the regenerative properties of different liver 
cell types. 
6.  Proliferating myofibroblasts that induce fibrosis in Dupuytrenʼs contracture 
localize in close proximity to blood vessels, which form a supportive niche 
for sustained cell proliferation.   
7.  The bFGF, IGF-2, and CTGF that are capable of activating AKT signaling 
potentially synergize in creating a favorable microenvironment for DC 
progression. 
8.  Small molecule compound NSC156529 is a new inhibitor of AKT1-PDPK1 
interaction and a new potential anti-tumor agent. NSC156529 reduces the 
activity of AKT signaling pathway, and growth of tumor cells in in vitro and 
in vivo. 
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SUMMARY IN ESTONIAN 
Terve ja kahjustatud maksa regeneratsioonis ning Dupuytrenʼi 
kontraktuuri progressioonis osalevate rakuliste ja 
molekulaarsete mehhanismide uurimine 
Maks on imetaja organismi suurim siseelund, millel on rohkem kui 500 erinevat 
funktsiooni. Maksa peamiste ülesannete hulka kuuluvad näiteks toksiliste ühen-
dite kahjutustamine, toitainete lagundamine, sapi tootmine seedimise hõlbus-
tamiseks, erinevate valkude sünteesimine ja metabolismiga seotud signaalirada-
de reguleerimine. Maksa tähtsus organismi normaalses talitluses tuleb kõige 
paremini esile maksatsirroosi (maksaparenhüüm on asendunud fibroosse arm-
koega) ja maksapuudulikkusega inimeste puhul, kelle maks ei suuda enam 
vajalikke protsesse läbi viia ning tihtipeale on nende ainsaks ravivõimaluseks 
maksasiirdamine. Lisaks maksa funktsioonide kadumisele tekivad maksatsirroo-
siga patsientidel sageli pahaloomulised maksakasvajad, mille esinemissagedus 
järjest kasvab. Kuna maksa siirdamine ei ole alati võimalik, on oluline välja 
töötada uusi alternatiivseid ravimeetodeid, mis takistaksid haiguse progressee-
rumist või pööraksid patoloogilised protsessid ümber. Võimalike ravisihtmär-
kide leidmiseks on vaja teada, millised rakud ja signaalirajad haiguse arengus 
osalevad. 
Normaalsetes tingimustes on maksal väga hea regeneratsioonivõime, kuid 
järjepidev kahjustus kurnab maksa taastumise potentsiaali, mille tagajärjel 
tekivad häired selle organi töös. Enamiku krooniliste maksahaiguste peamisteks 
tunnusteks on eellasrakupopulatsioonide ilmumine maksakoesse ning rakuvälise 
maatriksi ümberkorraldumine ja sünteesi suurenemine (fibrootilise koe teke). 
Nende tunnuste esinemise tase on positiivses korrelatsioonis fibroosi astmega 
ning tihtipeale esinevad eellasraku omadustega rakud ka maksakasvajates. 
Eellasrakud võivad diferentseeruda nii hepatotsüütideks kui sapijuharakkudeks, 
kuid nende päritolu on praegusel hetkel veel lahtine.  
Käesoleva töö üheks eesmärgiks oli välja selgitada, kas maksas esineb 
aeglaselt jagunevaid rakke ning kuidas need rakud osalevad maksa alalhoius ja 
taastumises. Kuna aeglane jagunemine on paljudele täiskasvanud organismi 
tüvirakkudele omane tunnus, otsustasime uurida selliste rakkude olemasolu 
maksas, kasutades transgeenset hiireliini, mis võimaldab detekteerida tuuma 
märke säilimist vähe jagunevates rakkudes. Leidsime, et hiire maksas paiknesid 
aeglaselt jagunevad rakud sapijuhades ning nad omasid diferentseerunud 
sapijuharaku tunnuseid. Need rakud ei osalenud maksa kahjustusejärgses taastu-
mises, kui regeneratsiooniks oli peamiselt vajalik hepatotsüütide jagunemine. 
Samas sapijuharakkude kahjustuse korral märkega rakud aktiveerusid ja 
kaotasid jagunemise tagajärjel oma tuuma märgistuse ning samuti ilmusid 
maksakoesse eellasrakud. Sellest järeldasime, et maksa aeglaselt jagunev raku-
populatsioon osaleb sapijuharakkude, aga mitte hepatotsüütide regeneratsioonis. 
In vitro katsed hiirest eraldatud rakkudega näitasid, et kuigi aeglaselt jagunevate 
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sapijuharakkude eneseuuendamise võime oli parem kui sama hiire normaalse 
jagunemiskiirusega sapijuharakkudel, ei olnud nad võimelised hepatotsüütideks 
diferentseeruma. Sellest järeldasime, et täiskasvanud hiire maksa aeglaselt 
jagunevad rakud on omavad kõrgenenud jagunemise potentsiaali, kuid oma 
diferentseerumise võime poolest on nad unipotentsed. 
Kuna maksahaigusi iseloomustab rakuvälise maatriksi ületootmine, uurisime 
proteoomi analüüsi abil kahjustusejärgseid muutusi maksa rakuvälises maat-
riksis. Leidsime, et lühiajaline CCl4 manustamine (akuutne hepatotsüütide kah-
justus) ja pikaajaline DDC manustamine (krooniline sapijuharakkude kahjustus) 
põhjustasid maatriksis erinevaid muutusi. Samuti avastasime, et erinevatel 
maatriksi komponentidel on hepatotsüütide ja sapijuharakkude proliferatsioo-
nile erinev mõju.   
Fibroosi uurimiseks kasutasime Dupuytrenʼi kontraktuuri patsientidelt 
eemaldatud fibroosse koe preparaate. Kuigi Dupuytrenʼi kontraktuur ei ole 
maksaga seotud haigus, on enamike fibrootiliste haiguste histoloogiline pilt ja 
peamised signaalirajad sarnased. Nägime, et vastupidiselt normaalsele koele 
sisaldas haige kude väga palju väikeseid veresooni, mille sees või läheduses 
paiknesid fibroosi põhjustavad prolifereeruvad müofibroblastid. Samuti avasta-
sime, et haige koe erinevad komponendid sünteesivad erinevaid fibroosi ja 
proliferatsiooni soodustavaid molekule, moodustades haiguse arenguks sobiliku 
keskonna. Lisaks leidsime, et Dupuytrenʼi kontraktuuri progressioonis võib ka 
higinäärmetel tähtis roll olla.  
Töö viimases osas keskendusime AKT1-PDPK1 interaktsiooni inhibiitori 
väljaselgitamisele. AKT signaalirada on ebanormaalselt aktiivne paljudes paha-
loomulistes kasvajates, sealhulgas maksakasvajates. Kuna PDPK1 on üks 
AKT1 aktivaatoritest, siis eeldasime, et nende omavahelise interaktsiooni 
lõhkumine võiks vähendada aktiivse AKT valgu taset. 2000 analüüsitud ühendi 
seast leidsime ühe väikesemolekulaarse ühendi (NSC156529), mis inhibeeris 
AKT1-PDPK1 interaktsiooni, vähendas aktiivse AKT valgu ja tema sihtmärk-
valkude taset ning pidurdas rakkude kasvu in vitro ja tuumori kasvu in vivo. 
Meie tulemused näitasid, et NSC156529 on ühend, millel võiks olla potentsiaali 
hüperaktiivse AKT signaalirajaga kasvajate-vastases ravis.  
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